Drugs / Blisibimod
Blisibimod
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02411136 | May 2005 → Aug 2007 | systemic lupus erythematosus | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT02443506 | Oct 2004 → Apr 2007 | systemic lupus erythematosus | Amgen | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT01598857 | Dec 2014 → Jun 2015 | granulomatosis with polyangiitis, microscopic polyangiitis | Anthera Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2 | NCT01305746 | Apr 2011 → Jul 2013 | systemic lupus erythematosus | Anthera Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01162681 | Jul 2010 → Apr 2012 | systemic lupus erythematosus | Anthera Pharmaceuticals | Completed | Missed primary |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT01609452 | Dec 2015 → Jun 2016 | autoimmune thrombocytopenic purpura | Anthera Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT02062684 | Jun 2013 → Mar 2017 | IgA glomerulonephritis | Anthera Pharmaceuticals | Completed | No outcome recorded |
| Phase 34 trials · 1 missed | ||||||
| Phase 3 | NCT02514967 | Jun → Nov 2016 | systemic lupus erythematosus | Anthera Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT02074020 | Dec 2015 → Jun 2018 | systemic lupus erythematosus | Anthera Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 3 | NCT02052219 | Oct 2014 → Oct 2016 | IgA glomerulonephritis | Anthera Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 3 | NCT01395745 | Feb 2013 → Jul 2016 | systemic lupus erythematosus | Anthera Pharmaceuticals | Completed | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Blisibimod | “Blisibimod is a potent B cell-activating factor (BAFF) antagonist” PMID 26290435 ↗ Aug 2015 |
| Known as | A-623 | “"peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind” PMID 26290435 ↗ Aug 2015 |
| Known as | AMG 623 | “"peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind” PMID 26290435 ↗ Aug 2015 |
| Action | Inhibit | “Tumor necrosis factor ligand superfamily member 13B inhibitor” CHEMBL2107877 ↗1“blisibimod, a BAFF inhibitor” PMID 29563108 ↗ Mar 2018 |
| Modality | Peptide | “"peptibody" blisibimod” PMID 26290435 ↗ Aug 2015 |
| Route | Subcutaneous | “High dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study” NCT01305746 ↗ |
| Target | TNFSF13B | “Tumor necrosis factor ligand superfamily member 13B inhibitor” CHEMBL2107877 ↗ |